Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 826

1.

Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy: The PRISMA-DTA Statement.

Frank RA, Bossuyt PM, McInnes MDF.

Radiology. 2018 Jul 3:180850. doi: 10.1148/radiol.2018180850. [Epub ahead of print] No abstract available.

PMID:
30015590
2.

Screening for child abuse by using a checklist and physical examinations in the emergency department led to the detection of more cases.

Teeuw AH, Kraan RBJ, van Rijn RR, Bossuyt PMM, Heymans HSA.

Acta Paediatr. 2018 Jul 10. doi: 10.1111/apa.14495. [Epub ahead of print]

PMID:
29992712
3.

VIEWPOINT: Defining endoscopic remission in ileocolonic Crohn's disease: let's start from scratch.

Bossuyt P, Louis E, Mary JY, Vermeire S, Bouhnik Y.

J Crohns Colitis. 2018 Jul 6. doi: 10.1093/ecco-jcc/jjy097. [Epub ahead of print]

PMID:
29982528
4.

Development and evaluating multimarker models for guiding treatment decisions.

Tajik P, Zafarmand MH, Zwinderman AH, Mol BW, Bossuyt PM.

BMC Med Inform Decis Mak. 2018 Jun 28;18(1):52. doi: 10.1186/s12911-018-0619-5.

5.

Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.

Mol BW, Bossuyt PM, Sunkara SK, Garcia Velasco JA, Venetis C, Sakkas D, Lundin K, Simón C, Taylor HS, Wan R, Longobardi S, Cottell E, D'Hooghe T.

Fertil Steril. 2018 Jun;109(6):968-979. doi: 10.1016/j.fertnstert.2018.04.037. Review.

6.

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.

Bossuyt P, Baert F, D'Heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, Ferrante M; Belgian IBD Research and Development Group .

Inflamm Bowel Dis. 2018 Jun 15. doi: 10.1093/ibd/izy219. [Epub ahead of print]

PMID:
29920582
7.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M.

Inflamm Bowel Dis. 2018 May 18. doi: 10.1093/ibd/izy155. [Epub ahead of print]

PMID:
29788318
8.

A large proportion of fecal immunochemical test-positive participants in colorectal cancer screening is symptomatic.

de Klerk CM, van der Vlugt M, Bossuyt PM, Dekker E.

United European Gastroenterol J. 2018 Apr;6(3):471-479. doi: 10.1177/2050640617733922. Epub 2017 Sep 24.

9.

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.

De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, Ferrante M, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD).

United European Gastroenterol J. 2018 Apr;6(3):439-445. doi: 10.1177/2050640617722310. Epub 2017 Jul 26.

10.

Prognostic value of cardiovascular parameters in computed tomography pulmonary angiography in patients with acute pulmonary embolism.

Beenen LFM, Bossuyt PMM, Stoker J, Middeldorp S.

Eur Respir J. 2018 Jul 4;52(1). pii: 1702611. doi: 10.1183/13993003.02611-2017. Print 2018 Jul.

PMID:
29773691
11.

The FOAM study: is Hysterosalpingo foam sonography (HyFoSy) a cost-effective alternative for hysterosalpingography (HSG) in assessing tubal patency in subfertile women? Study protocol for a randomized controlled trial.

van Rijswijk J, van Welie N, Dreyer K, van Hooff MHA, de Bruin JP, Verhoeve HR, Mol F, Kleiman-Broeze KA, Traas MAF, Muijsers GJJM, Manger AP, Gianotten J, de Koning CH, Koning AMH, Bayram N, van der Ham DP, Vrouenraets FPJM, Kalafusova M, van de Laar BIG, Kaijser J, van Oostwaard MF, Meijer WJ, Broekmans FJM, Valkenburg O, van der Voet LF, van Disseldorp J, Lambers MJ, Peters HE, Lier MCI, Lambalk CB, van Wely M, Bossuyt PMM, Stoker J, van der Veen F, Mol BWJ, Mijatovic V.

BMC Womens Health. 2018 May 9;18(1):64. doi: 10.1186/s12905-018-0556-6.

12.

Diffusion-weighted MRI in inflammatory bowel disease.

Pouillon L, Laurent V, Pouillon M, Bossuyt P, Bonifacio C, Danese S, Deepak P, Loftus EV Jr, Bruining DH, Peyrin-Biroulet L.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):433-443. doi: 10.1016/S2468-1253(18)30054-2. Review.

PMID:
29739674
13.

Questioning the use of an age-adjusted D-dimer threshold to exclude venous thromboembolism: comment.

Kraaijpoel N, Toorop MMA, Bossuyt PM, Klok FA, Büller HR, van Es N.

J Thromb Haemost. 2018 Jul;16(7):1445-1448. doi: 10.1111/jth.14133. Epub 2018 Jun 12. No abstract available.

PMID:
29733495
14.

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

Van de Vondel S, Baert F, Reenaers C, Vanden Branden S, Amininejad L, Dewint P, Van Moerkercke W, Rahier JF, Hindryckx P, Bossuyt P, Ferrante M; Belgian IBD Research and Development (BIRD) .

Inflamm Bowel Dis. 2018 Apr 23;24(5):1099-1105. doi: 10.1093/ibd/izx103.

PMID:
29668947
15.

Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.

Strik AS, van de Vrie W, Bloemsaat-Minekus JPJ, Nurmohamed M, Bossuyt PJJ, Bodelier A, Rispens T, van Megen YJB, D'Haens GR; SECURE study group.

Lancet Gastroenterol Hepatol. 2018 Jun;3(6):404-412. doi: 10.1016/S2468-1253(18)30082-7. Epub 2018 Mar 30.

PMID:
29606564
16.

From the theoretical to the practical: how to evaluate the ethical and scientific justifications of randomized clinical trials.

Olsen M, Sharp MK, Bossuyt PM.

J Clin Epidemiol. 2018 Jul;99:170-171. doi: 10.1016/j.jclinepi.2018.03.008. Epub 2018 Mar 26. No abstract available.

17.

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).

Franchimont D, Ferrante M, Louis E, De Vos M, Dewit O, Van Hootegem P, Moreels T, Liefferinckx C, Bossuyt P, Baert F, Rahier JF, Vermeire S.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):49-53. No abstract available.

PMID:
29562378
18.

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.

Peeters H, Louis E, Baert F, Dewit O, Coche JC, Ferrante M, Lambrecht G, Colard A, Van Gossum A, Bossuyt P, Moreels T, Vander Cruyssen B, Gils A, De Vos M.

Acta Gastroenterol Belg. 2018 Jan-Mar;81(1):15-21.

PMID:
29562373
19.

Natural conception rates in couples with unexplained or mild male subfertility scheduled for fertility treatment: a secondary analysis of a randomized controlled trial.

van Eekelen R, Tjon-Kon-Fat RI, Bossuyt PMM, van Geloven N, Eijkemans MJC, Bensdorp AJ, van der Veen F, Mol BW, van Wely M.

Hum Reprod. 2018 May 1;33(5):919-923. doi: 10.1093/humrep/dey051.

PMID:
29538638
20.

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease.

Bossuyt P, Debeuckelaere C, Ferrante M, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S.

Eur J Gastroenterol Hepatol. 2018 May;30(5):539-545. doi: 10.1097/MEG.0000000000001091.

PMID:
29462028
21.

Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.

van der Vlugt M, Grobbee EJ, Bossuyt PM, Bos ACRK, Kuipers EJ, Lansdorp-Vogelaar I, Spaander MCW, Dekker E.

Clin Gastroenterol Hepatol. 2018 Feb 7. pii: S1542-3565(18)30107-1. doi: 10.1016/j.cgh.2018.01.037. [Epub ahead of print]

PMID:
29427732
22.

Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!

Jaboli F, Pouillon L, Bossuyt P, Danese S, Peyrin-Biroulet L.

Gastroenterology. 2018 Mar;154(4):1196-1198. doi: 10.1053/j.gastro.2018.01.036. Epub 2018 Jan 31. No abstract available.

PMID:
29391131
23.

Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.

McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM; the PRISMA-DTA Group, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L, Hunt HA, Hyde CJ, Korevaar DA, Leeflang MMG, Macaskill P, Reitsma JB, Rodin R, Rutjes AWS, Salameh JP, Stevens A, Takwoingi Y, Tonelli M, Weeks L, Whiting P, Willis BH.

JAMA. 2018 Jan 23;319(4):388-396. doi: 10.1001/jama.2017.19163.

PMID:
29362800
24.

Reply.

van der Vlugt M, Dekker E, Bossuyt PM.

Gastroenterology. 2018 Feb;154(3):763-764. doi: 10.1053/j.gastro.2018.01.020. Epub 2018 Jan 17. No abstract available.

PMID:
29352953
25.

Current and Emerging Multianalyte Assays with Algorithmic Analyses-Are Laboratories Ready for Clinical Adoption?

Colón-Franco JM, Bossuyt PMM, Algeciras-Schimnich A, Bird C, Engstrom-Melnyk J, Fleisher M, Kattan M, Lambert-Messerlian G.

Clin Chem. 2018 Jun;64(6):885-891. doi: 10.1373/clinchem.2017.275677. Epub 2018 Jan 17. No abstract available.

PMID:
29343536
26.

The FIGO Stage IVA Versus IVB of Ovarian Cancer: Prognostic Value and Predictive Value for Neoadjuvant Chemotherapy.

Tajik P, van de Vrie R, Zafarmand MH, Coens C, Buist MR, Vergote I, Bossuyt PMM, Kenter GG.

Int J Gynecol Cancer. 2018 Mar;28(3):453-458. doi: 10.1097/IGC.0000000000001186.

PMID:
29324537
27.

Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.

D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID.

Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6.

PMID:
29317275
28.

The development of CHAMP: a checklist for the appraisal of moderators and predictors.

van Hoorn R, Tummers M, Booth A, Gerhardus A, Rehfuess E, Hind D, Bossuyt PM, Welch V, Debray TPA, Underwood M, Cuijpers P, Kraemer H, van der Wilt GJ, Kievit W.

BMC Med Res Methodol. 2017 Dec 21;17(1):173. doi: 10.1186/s12874-017-0451-0.

29.

Cost-effectiveness of curettage vs. expectant management in women with an incomplete evacuation after misoprostol treatment for first-trimester miscarriage: a randomized controlled trial and cohort study.

Lemmers M, Verschoor MAC, Bossuyt PM, Huirne JAF, Spinder T, Nieboer TE, Bongers MY, Janssen IAH, Van Hooff MHA, Mol BWJ, Ankum WM, Bosmans JE; MisoREST study group.

Acta Obstet Gynecol Scand. 2018 Mar;97(3):294-300. doi: 10.1111/aogs.13283. Epub 2018 Jan 19.

PMID:
29266169
30.

Are Study and Journal Characteristics Reliable Indicators of "Truth" in Imaging Research?

Frank RA, McInnes MDF, Levine D, Kressel HY, Jesurum JS, Petrcich W, McGrath TA, Bossuyt PM.

Radiology. 2018 Apr;287(1):215-223. doi: 10.1148/radiol.2017170586. Epub 2017 Nov 27. Review.

PMID:
29173122
31.

Selecting pH cut-offs for the safe verification of nasogastric feeding tube placement: a decision analytical modelling approach.

Ni MZ, Huddy JR, Priest OH, Olsen S, Phillips LD, Bossuyt PMM, Hanna GB.

BMJ Open. 2017 Nov 4;7(11):e018128. doi: 10.1136/bmjopen-2017-018128. Erratum in: BMJ Open. 2018 Jan 21;8(1):e018128corr1.

32.

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.

Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.

Lancet. 2018 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31. Erratum in: Lancet. 2018 Dec 23;390(10114):2768.

PMID:
29096949
33.

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Dreesen E, Bossuyt P, Mulleman D, Gils A, Pascual-Salcedo D.

Clin Pharmacol. 2017 Oct 3;9:101-111. doi: 10.2147/CPAA.S138414. eCollection 2017. Review.

34.

Recommendations for reporting of systematic reviews and meta-analyses of diagnostic test accuracy: a systematic review.

McGrath TA, Alabousi M, Skidmore B, Korevaar DA, Bossuyt PMM, Moher D, Thombs B, McInnes MDF.

Syst Rev. 2017 Oct 10;6(1):194. doi: 10.1186/s13643-017-0590-8. Review.

35.

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model.

Bossuyt P, Debeuckelaere C, Ferrante M, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S.

J Crohns Colitis. 2018 Jan 5;12(1):32-38. doi: 10.1093/ecco-jcc/jjx110.

PMID:
28981768
36.

Evaluation of an online family history tool for identifying hereditary and familial colorectal cancer.

Kallenberg FGJ, Aalfs CM, The FO, Wientjes CA, Depla AC, Mundt MW, Bossuyt PMM, Dekker E.

Fam Cancer. 2018 Jul;17(3):371-380. doi: 10.1007/s10689-017-0041-7.

37.

Decision making about healthcare-related tests and diagnostic test strategies. Paper 4: International guidelines show variability in their approaches.

Mustafa RA, Wiercioch W, Arevalo-Rodriguez I, Cheung A, Prediger B, Ivanova L, Ventresca M, Brozek J, Santesso N, Bossuyt P, Garg AX, Lloyd N, Lelgemann M, Bühler D, Schünemann HJ.

J Clin Epidemiol. 2017 Dec;92:38-46. doi: 10.1016/j.jclinepi.2017.09.004. Epub 2017 Sep 14. Review.

PMID:
28917630
38.

Decision making about healthcare-related tests and diagnostic test strategies. Paper 3: a systematic review shows limitations in most tools designed to assess quality and develop recommendations.

Mustafa RA, Wiercioch W, Falavigna M, Zhang Y, Ivanova L, Arevalo-Rodriguez I, Cheung A, Prediger B, Ventresca M, Brozek J, Santesso N, Bossuyt P, Garg AX, Lloyd N, Lelgemann M, Bühler D, Schünemann HJ.

J Clin Epidemiol. 2017 Dec;92:29-37. doi: 10.1016/j.jclinepi.2017.09.007. Epub 2017 Sep 12. Review.

PMID:
28916490
39.

Decision making about healthcare-related tests and diagnostic test strategies. Paper 2: a review of methodological and practical challenges.

Mustafa RA, Wiercioch W, Cheung A, Prediger B, Brozek J, Bossuyt P, Garg AX, Lelgemann M, Büehler D, Schünemann HJ.

J Clin Epidemiol. 2017 Dec;92:18-28. doi: 10.1016/j.jclinepi.2017.09.003. Epub 2017 Sep 12. Review.

PMID:
28916488
40.

Comparison of Spectrophotometry, Chromate Inhibition, and Cytofluorometry Versus Gene Sequencing for Detection of Heterozygously Glucose-6-Phosphate Dehydrogenase-Deficient Females.

Peters AL, Veldthuis M, van Leeuwen K, Bossuyt PMM, Vlaar APJ, van Bruggen R, de Korte D, Van Noorden CJF, van Zwieten R.

J Histochem Cytochem. 2017 Nov;65(11):627-636. doi: 10.1369/0022155417730021. Epub 2017 Sep 13.

PMID:
28902532
41.

E-health in inflammatory bowel diseases: More challenges than opportunities?

Bossuyt P, Pouillon L, Bonnaud G, Danese S, Peyrin-Biroulet L.

Dig Liver Dis. 2017 Dec;49(12):1320-1326. doi: 10.1016/j.dld.2017.08.026. Epub 2017 Aug 24.

PMID:
28899622
42.

Adrenal Lesions in Patients With (Attenuated) Familial Adenomatous Polyposis and MUTYH-Associated Polyposis.

Kallenberg FGJ, Bastiaansen BAJ, Nio CY, Soeters MR, Boermeester MA, Aalfs CM, Bossuyt PMM, Dekker E.

Dis Colon Rectum. 2017 Oct;60(10):1057-1064. doi: 10.1097/DCR.0000000000000809.

PMID:
28891849
43.

Management of patients with inflammatory bowel disease and spondyloarthritis.

Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L.

Expert Rev Clin Pharmacol. 2017 Dec;10(12):1363-1374. doi: 10.1080/17512433.2017.1377609. Epub 2017 Sep 20. Review.

PMID:
28879780
44.

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.

Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group.

Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Erratum in: Lancet Gastroenterol Hepatol. 2017 Nov;2(11):e7.

PMID:
28838644
45.

Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism: A Systematic Review and Meta-analysis of Individual Patient Data.

van Es N, Le Gal G, Otten HM, Robin P, Piccioli A, Lecumberri R, Jara-Palomares L, Religa P, Rieu V, Rondina M, Beckers MM, Prandoni P, Salaun PY, Di Nisio M, Bossuyt PM, Büller HR, Carrier M.

Ann Intern Med. 2017 Sep 19;167(6):410-417. doi: 10.7326/M17-0868. Epub 2017 Aug 22. Review.

PMID:
28828492
46.

STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts.

Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group.

BMJ. 2017 Aug 17;358:j3751. doi: 10.1136/bmj.j3751. No abstract available.

PMID:
28819063
47.

Tofacitinib Is the Right OCTAVE for Ulcerative Colitis.

Pouillon L, Bossuyt P, Peyrin-Biroulet L.

Gastroenterology. 2017 Sep;153(3):862-864. doi: 10.1053/j.gastro.2017.07.027. Epub 2017 Jul 27. No abstract available.

PMID:
28757262
48.

[A fact-free medicine? Report by Dutch Council for Public Health and Society is slap in the face].

Bossuyt PMM.

Ned Tijdschr Geneeskd. 2017;161(0):D1901. Dutch.

PMID:
28745258
49.

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.

Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B.

Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Review.

PMID:
28721928
50.

Prognostic accuracy of cerebroplacental ratio and middle cerebral artery Doppler for adverse perinatal outcome: systematic review and meta-analysis.

Vollgraff Heidweiller-Schreurs CA, De Boer MA, Heymans MW, Schoonmade LJ, Bossuyt PMM, Mol BWJ, De Groot CJM, Bax CJ.

Ultrasound Obstet Gynecol. 2018 Mar;51(3):313-322. doi: 10.1002/uog.18809. Epub 2018 Feb 5. Review.

Supplemental Content

Loading ...
Support Center